Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

FDA
News

Karyopharm Therapeutics Received FDA Approval for Labeling for XPOVIO

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208088

byCharles Gross

March 29, 2022

1 minute read

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208088

Loop Capital Initiates Coverage On Colfax with Hold Rating, Announces Price Target of $45

By Benzinga Newsdesk

Today, 6:39 AM

Loop Capital analyst Chris Dankert initiates coverage on Colfax (NYSE:CFX) with a Hold rating and announces Price Target of $45.

CFX

Here’s How Much $100 Invested In Aon 10 Years Ago Would Be Worth Today

By Benzinga Insights

Today, 6:39 AM

Aon (NYSE:AON) has outperformed the market over the past 10 years by 7.5% on an annualized basis producing an average annual return of 19.59%. Currently, Aon has a market capitalization of $58.99 billion.

AON

Raymond James Downgrades Premier Financial to Market Perform

By Benzinga Newsdesk

Today, 6:39 AM

Raymond James analyst David Long downgrades Premier Financial (NASDAQ:PFC) from Outperform to Market Perform.

PFC

News

Kohl’s Corporation CEO Says ‘We Are Seeing Customers Make Fewer Shopping Trips, Spend Less Per Transaction And Shift Towards Our Value-oriented Private Brands’

By Benzinga Newsdesk

Today, 6:39 AM

-Reuters

KSS

Karyopharm Therapeutics Received FDA Approval for Labeling for XPOVIO

Related Posts

Loop Capital Initiates Coverage On Colfax with Hold Rating, Announces Price Target of $45

Here’s How Much $100 Invested In Aon 10 Years Ago Would Be Worth Today

Raymond James Downgrades Premier Financial to Market Perform

Kohl’s Corporation CEO Says ‘We Are Seeing Customers Make Fewer Shopping Trips, Spend Less Per Transaction And Shift Towards Our Value-oriented Private Brands’